AVADEL PHARMACEUTICALS PLC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Net product revenue
Product sales
License revenue
Total net product revenue

Cost of products sold
Gross profit
Operating expenses:
Research and development expenses
Selling, general and administrative expenses
Intangible asset amortization
Changes in fair value of contingent consideration
Gain on sale of Hospital Products
Impairment of intangible asset
Restructuring expense
Total operating expenses

Operating loss
Investment and other income (expense), net
Loss on deconsolidation of subsidiary
Other expense - changes in fair value of contingent consideration payable
Interest expense
Loss before income taxes
Income tax (benefit) provision
Net loss
Net loss per share - basic (in dollars per share)
Net loss per share - diluted (in dollars per share)
Weighted average number of shares outstanding - basic (in shares)
Weighted average number of shares outstanding - diluted (in shares)

Comments